Recent Updates
Recently added Catalysts
MLYS Positive Sentiment Score: 70/100

Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023

Key Takeaway: Mineralys Therapeutics, a clinical-stage biopharmaceutical company, is set to participate in the Bank of America Securities 2023 Health Care Conference on May 10, 2023. The company's CEO, Jon Congleton, and CFO, Adam Levy, will engage in a fireside chat during the event. This highlights Mineralys' focus on developing treatments targeting diseases related to elevated aldosterone levels, particularly their candidate lorundrostat for uncontrolled hypertension. The event indicates the company's ongoing commitment to engaging with investors and the healthcare community.

Market Sentiment Analysis

POSITIVE FACTORS

  • Mineralys Therapeutics is actively participating in a notable health care conference.
  • The company is focused on developing innovative treatments for uncontrolled hypertension.
  • The CEO's participation highlights the company's commitment to investor relations.

Full Press Release Details

RADNOR, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton and Chief Financial Officer and Chief Business Officer Adam Levy will participate in a fireside chat at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 5 p.m. PT
The live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcast will be available on the Company’s website for approximately 90 days.
Bank of America Securities 2023 Health Care Conference:
Date: Wednesday, May 10, 2023
Time: 5:00 p.m. PT
Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension.
Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn.
Elixir Health Public Relations
Phone: (1) 515-707-9678

Frequently Asked Questions

What is the focus of Mineralys Therapeutics?

Mineralys Therapeutics specializes in developing treatments for diseases linked to elevated aldosterone.

When will the fireside chat at the conference occur?

The fireside chat is scheduled for May 10, 2023, at 5 p.m. PT.

How can I access the webcast of the fireside chat?

The webcast can be accessed on the Investor Relations section of the Mineralys website.

What is the initial product candidate from Mineralys?

Mineralys's first product candidate is lorundrostat, an aldosterone synthase inhibitor.

Where is Mineralys Therapeutics located?

Mineralys Therapeutics is based in Radnor, Pennsylvania.

Last updated: Apr 27, 2023